List of bibliographic references
Number of relevant bibliographic references: 6.
| Ident. | Authors (with country if any) | Title |
|---|
| 000015 (2017) |
Felicia T. Roncolato [Australie] ; Dominique Berton-Rigaud [France] ; Rachel O'Connell [Australie] ; Anne Lanceley [Royaume-Uni] ; Jalid Sehouli [Allemagne] ; Luke Buizen [Australie] ; Aikou Okamoto [Japon] ; Eriko Aotani [Japon] ; Domenica Lorusso [Italie] ; Paul Donnellan [Irlande (pays)] ; Amit Oza [Canada] ; Elisabeth Avall-Lundqvist [Suède] ; Jonathan Berek [États-Unis] ; Felix Hilpert [Allemagne] ; Jonathan A. Ledermann [Royaume-Uni] ; Marie Christine Kaminsky [France] ; Martin R. Stockler [Australie] ; Madeleine T. King [Australie] ; Michael Friedlander [Australie] | Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). |
| 000088 (2017) |
Robert L. Coleman [États-Unis] ; Amit M. Oza [Canada] ; Domenica Lorusso [Italie] ; Carol Aghajanian [États-Unis] ; Ana Oaknin [Espagne] ; Andrew Dean [Australie] ; Nicoletta Colombo [Italie] ; Johanne I. Weberpals [Canada] ; Andrew Clamp [Royaume-Uni] ; Giovanni Scambia [Italie] ; Alexandra Leary [France] ; Robert W. Holloway [États-Unis] ; Margarita Amenedo Gancedo [Espagne] ; Peter C. Fong [Nouvelle-Zélande] ; Jeffrey C. Goh [Australie] ; David M. O'Malley [États-Unis] ; Deborah K. Armstrong [États-Unis] ; Jesus Garcia-Donas [Espagne] ; Elizabeth M. Swisher [États-Unis] ; Anne Floquet [France] ; Gottfried E. Konecny [États-Unis] ; Iain A. Mcneish [Royaume-Uni] ; Clare L. Scott [Australie] ; Terri Cameron [États-Unis] ; Lara Maloney [États-Unis] ; Jeff Isaacson [États-Unis] ; Sandra Goble [États-Unis] ; Caroline Grace [États-Unis] ; Thomas C. Harding [États-Unis] ; Mitch Raponi [États-Unis] ; James Sun [États-Unis] ; Kevin K. Lin [États-Unis] ; Heidi Giordano [États-Unis] ; Jonathan A. Ledermann [Royaume-Uni] | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000154 (2017) |
Eric Pujade-Lauraine [France] ; Jonathan A. Ledermann [Royaume-Uni] ; Frédéric Selle [France] ; Val Gebski [Australie] ; Richard T. Penson [États-Unis] ; Amit M. Oza [Canada] ; Jacob Korach [Israël] ; Tomasz Huzarski [Pologne] ; Andrés Poveda [Espagne] ; Sandro Pignata [Italie] ; Michael Friedlander [Australie] ; Nicoletta Colombo [Italie] ; Philipp Harter [Allemagne] ; Keiichi Fujiwara [Japon] ; Isabelle Ray-Coquard [France] ; Susana Banerjee [Royaume-Uni] ; Joyce Liu [États-Unis] ; Elizabeth S. Lowe [États-Unis] ; Ralph Bloomfield [Royaume-Uni] ; Patricia Pautier [France] | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. |
| 000464 (2016) |
Stephanie M. De Boer [Pays-Bas] ; Melanie E. Powell [Royaume-Uni] ; Linda Mileshkin [Australie] ; Dionyssios Katsaros [Italie] ; Paul Bessette [Canada] ; Christine Haie-Meder [France] ; Petronella B. Ottevanger [Pays-Bas] ; Jonathan A. Ledermann [Royaume-Uni] ; Pearly Khaw [Australie] ; Alessandro Colombo [Italie] ; Anthony Fyles [Canada] ; Marie-Helene Baron [France] ; Henry C. Kitchener [Royaume-Uni] ; Hans W. Nijman [Pays-Bas] ; Roy F. Kruitwagen [Pays-Bas] ; Remi A. Nout [Pays-Bas] ; Karen W. Verhoeven-Adema [Pays-Bas] ; Vincent T. Smit [Pays-Bas] ; Hein Putter [Pays-Bas] ; Carien L. Creutzberg [Pays-Bas] | Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. |
| 000837 (2015) |
Amit M. Oza [Canada] ; Adrian D. Cook [Royaume-Uni] ; Jacobus Pfisterer [Allemagne] ; Andrew Embleton [Royaume-Uni] ; Jonathan A. Ledermann [Royaume-Uni] ; Eric Pujade-Lauraine [France] ; Gunnar Kristensen [Norvège] ; Mark S. Carey [Canada] ; Philip Beale [Australie] ; Andrés Cervantes [Espagne] ; Tjoung-Won Park-Simon [Allemagne] ; Gordon Rustin [Royaume-Uni] ; Florence Joly [France] ; Mansoor R. Mirza [Danemark] ; Marie Plante [Canada] ; Michael Quinn [Australie] ; Andrés Poveda [Espagne] ; Gordon C. Jayson [Royaume-Uni] ; Dan Stark [Royaume-Uni] ; Ann Marie Swart [Royaume-Uni] ; Laura Farrelly [Royaume-Uni] ; Richard Kaplan [Royaume-Uni] ; Mahesh K B. Parmar [Royaume-Uni] ; Timothy J. Perren [Royaume-Uni] | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial |
| 001417 (2011) |
Timothy J. Perren [Royaume-Uni] ; Ann Marie Swart [États-Unis] ; Jacobus Pfisterer [Allemagne] ; Jonathan A. Ledermann [Royaume-Uni] ; Eric Pujade-Lauraine [France] ; Gunnar Kristensen [Norvège] ; Mark S. Carey [Canada] ; Philip Beale [Australie] ; Andres Cervantes ; Christian Kurzeder [Allemagne] ; Andreas Du Bois [Allemagne] ; Jalid Sehouli ; Rainer Kimmig [Allemagne] ; Anne St Hle [Allemagne] ; Fiona Collinson [Royaume-Uni] ; Sharadah Essapen [Royaume-Uni] ; Charlie Gourley ; Alain Lortholary ; Frédéric Selle ; Mansoor R. Mirza ; Arto Leminen ; Marie Plante [Canada] ; Dan Stark [Royaume-Uni] ; WENDI QIAN [Royaume-Uni, États-Unis] ; Mahesh K. B. Parmar [États-Unis] ; Amit M. Oza | A Phase 3 Trial of Bevacizumab in Ovarian Cancer |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Female |
| 3 | Humans |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Bevacizumab |
| 2 | Carboplatin (administration & dosage) |
| 2 | Middle Aged |
| 2 | Neoplasm Grading |
| 2 | Neoplasm Staging |
| 2 | Ovarian Neoplasms (drug therapy) |
| 2 | Ovarian Neoplasms (pathology) |
| 2 | Paclitaxel (administration & dosage) |
| 1 | Adenocarcinoma, Clear Cell (radiotherapy) |
| 1 | Adenocarcinoma, Clear Cell (secondary) |
| 1 | Adenocarcinoma, Clear Cell (therapy) |
| 1 | Aged |
| 1 | Antiangiogenic agent |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Antineoplastic agent |
| 1 | Australia |
| 1 | Canada |
| 1 | Case-Control Studies |
| 1 | Chemoradiotherapy, Adjuvant (adverse effects) |
| 1 | Cisplatin (administration & dosage) |
| 1 | Cystadenocarcinoma, Serous (radiotherapy) |
| 1 | Cystadenocarcinoma, Serous (secondary) |
| 1 | Cystadenocarcinoma, Serous (therapy) |
| 1 | Disease Progression |
| 1 | Disease-Free Survival |
| 1 | Double-Blind Method |
| 1 | Drug Administration Schedule |
| 1 | Endometrial Neoplasms (pathology) |
| 1 | Endometrial Neoplasms (radiotherapy) |
| 1 | Endometrial Neoplasms (therapy) |
| 1 | Europe |
| 1 | Follow-Up Studies |
| 1 | Gastrointestinal Diseases (diagnosis) |
| 1 | Gastrointestinal Diseases (etiology) |
| 1 | Genes, BRCA1 |
| 1 | Genes, BRCA2 |
| 1 | Hematologic Diseases (diagnosis) |
| 1 | Hematologic Diseases (etiology) |
| 1 | Immunomodulator |
| 1 | Infusions, Intravenous |
| 1 | Intention to Treat Analysis |
| 1 | Lymphatic Metastasis |
| 1 | Maintenance Chemotherapy |
| 1 | Malignant tumor |
| 1 | Medicine |
| 1 | Mutation |
| 1 | Neoplasm Invasiveness |
| 1 | Nervous System Diseases (diagnosis) |
| 1 | Nervous System Diseases (etiology) |
| 1 | New Zealand |
| 1 | Ovarian Neoplasms (genetics) |
| 1 | Ovarian Neoplasms (mortality) |
| 1 | Ovary cancer |
| 1 | Phase III trial |
| 1 | Phthalazines (therapeutic use) |
| 1 | Piperazines (therapeutic use) |
| 1 | Prognosis |
| 1 | Quality of Life |
| 1 | Radiotherapy, Adjuvant (adverse effects) |
| 1 | Survival Analysis |
| 1 | Survival Rate |
| 1 | Tablets |
| 1 | Time Factors |
| 1 | Treatment Outcome |
| 1 | Vascular endothelium growth factor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Jonathan A. Ledermann"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Jonathan A. Ledermann" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Jonathan A. Ledermann
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
